Details for Patent: 10,449,146
✉ Email this page to a colleague
Which drugs does patent 10,449,146 protect, and when does it expire?
Patent 10,449,146 protects KYNMOBI and is included in one NDA.
This patent has seven patent family members in four countries.
Summary for Patent: 10,449,146
| Title: | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa |
| Abstract: | Methods and pharmaceutical unit dosage forms for treating Parkinson's disease in a subject (e.g., an "off" episode in a subject having Parkinson's disease) are described. The pharmaceutical unit dosage forms are films having a first portion including particles containing an acid addition salt of apomorphine and a second portion containing a pH neutralizing agent. The pharmaceutical unit dosage forms can be flexible and have toughness greater than 100 g.times.mm. The methods can involve administering to a subject having Parkinson's disease a therapeutic dose sufficient to produce an apomorphine plasma concentrate of at least 2.64 ng/mL within 45 minutes after the administration. The subject may be identified as having low uptake, medium uptake, or high uptake of apomorphine administered via oral mucosa. |
| Inventor(s): | Barnhart; Scott David (York, PA), Koons; Michael Clinton (York, PA), Hariharan; Madhu Sudan (Greensboro, NC), Dubow; Jordan (Glencoe, IL), Bilbault; Thierry (Toronto, CA), Giovinazzo; Anthony John (Caledon, CA) |
| Assignee: | Sunovion Pharmaceuticals Inc. (Marlborough, MA) |
| Application Number: | 15/789,528 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 10,449,146
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-001 | May 21, 2020 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE | ⤷ Try a Trial | ||||
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-002 | May 21, 2020 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE | ⤷ Try a Trial | ||||
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-003 | May 21, 2020 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,449,146
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 3019769 | ⤷ Try a Trial | |||
| Canada | 3127926 | ⤷ Try a Trial | |||
| European Patent Office | 3285771 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
